Geng report on: Prevention and management of adult obesity: 2025 annual progress and trends from six keywords

Academic fraud report · Geng Detector

Summary

This report evaluates a narrative/review-type article published in Chinese General Practice (DOI: 10.12114/j.issn.1007-9572.2026.0035), titled "Prevention and management of adult obesity: 2025 annual progress and trends from six keywords" by Chen Xiangyang, Huang Hongmei, and Li Sheyu. The verdict is that the paper is CLEAN. Because the article is an annual progress review (综述) containing no original experimental images, raw datasets, statistical plots, or RCT data tables, the image-duplication, data-fabrication, image-splicing, and statistical-anomaly detection dimensions could not be triggered. The only substantive concern identified is a factual/transcription error in Table 2's footnote, where Retatrutide (a GLP-1/GIP/GCG tri-agonist) is equated with Cagrilintide (an amylin analogue), despite the same footnote correctly defining CagriSema as the combination of Cagrilintide and Semaglutide. This appears to be an inadvertent copy-paste or typographical mistake. Additional garbled characters in headers/footers are likely PDF conversion artifacts or watermarking residue, not academic misconduct. Confidence is high that no fraud exists; limits include the inability of automated checks to validate every cited source.

Verdict

✅ Clean. The paper is a narrative review with no original experimental data, so the standard image-duplication, data-fabrication, image-splicing, and statistical-anomaly checks are not applicable. No evidence of academic fraud was found.

Key findings

The manuscript is a 综述 (narrative review/annual progress article); no original figures, blots, microscopy images, raw clinical data tables, or statistical plots are present, so the core Geng-style data-integrity checks cannot be triggered.
A factual/transcription error exists in the Table 2 note, where "Retatrutide = 卡格列肽" equates Retatrutide (a GLP-1/GIP/GCG triple agonist) with Cagrilintide (an amylin analogue). These are two distinct molecules. In the same footnote, "CagriSema = 卡格列肽和司美格鲁肽的合剂" is stated correctly, suggesting a copy-paste or editing slip rather than a substantive error.
Garbled Latin-character strings in page headers/footers (e.g., N( & N B J M [ H R L Z Y ! D I J O B H Q O F U D O, & mail: [g R Lyx !c Iinag Q net cn) are consistent with PDF conversion artifacts, OCR residue, or embedded anti-piracy/blind-review watermarking rather than academic misconduct.

Evidence highlights

DOI: 10.12114/j.issn.1007-9572.2026.0035
Source PDF: 202605.00109v1.pdf
Table 2 footnote error: "Retatrutide= 卡格列肽" — Retatrutide is a GLP-1/GIP/GCG tri-receptor agonist; Cagrilintide (卡格列肽) is an amylin analogue. The conflation is pharmacologically incorrect.
Same Table 2 footnote, line 1: "CagriSema= 卡格列肽和司美格鲁肽的合剂" is consistent with current literature.
Header/footer artifacts: non-meaningful Latin-character sequences appear in header regions and near an email fragment (corresponds plausibly to the corresponding author's mailbox at the journal's net.cn domain).

Notes

Severity rating for the Table 2 footnote error: 🟡 Questionable — appears to be an inadvertent authoring/typesetting slip; does not affect the review's overall conclusions.
Severity rating for header/footer garbled text: 🟢 Benign — likely PDF/watermark artifacts.
Severity rating for image and data integrity checks: 🟢 Not applicable (N/A) for a review article with no primary data.
Recommended follow-up: a polite erratum/correspondence to the corresponding author regarding the Table 2 footnote; no need to request raw data.
This report is AI-assisted and intended for academic discussion only; any formal determination of misconduct should be made by a qualified investigative body.